Shots: Bain Capital and Cinven to acquire Lonza’s specialty ingredients business and operations for an enterprise value of $4.7B. The transaction is expected to close in H2’21 The divestiture will […]readmore
Tags : Divest
Shots: Corza Health to acquire the assets and licenses supporting the development and commercialization of TachoSil while Takeda will retain its ownership of the manufacturing facility in Linz and Austria. […]readmore
Shots: Takeda and Blackstone sign an agreement to divest it consumer health care business unit for $2.3B. The transaction expected to be closed by Mar 31, 2021 The portfolio to […]readmore
Shots: Takeda has signed an agreement with Celltrion to divest 18 select OTC and prescription pharmaceutical assets exclusively commercialized in the Asia Pacific under which Takeda will receive $266M as […]readmore
Shots: Takeda to receive $505M cash at closing, $70M in non-contingent cash to be paid within 4yrs. post-closing, $95M as milestones. Takeda will divest ~110 select OTC and prescription pharmaceutical […]readmore
Shots: Takeda will divest a portfolio of ~18 select OTC and prescription pharmaceutical assets including Neosaldina, Nesina, and Dramin sold in Brazil, Mexico, Argentina, Colombia, Ecuador, Panama and Peru to […]readmore
Shots: Merck KGaA divests its allergy business, Allergopharm to Dermapharm to focus on developing innovative therapies targeting the unmet medical needs of patients with difficult-to-treat diseases. The transaction is anticipated […]readmore
Shots: AstraZeneca to receive $350M up front, up to $40M as commercial milestones b/w 2020 to 2022. Atnahs to get global commercial rights (Ex- US, India and Japan) of Inderal […]readmore
Shots: Allergan will divest its brazikumab to AstraZeneca including its global development and commercialization rights while Nestle to acquire complete ownership of Zenpep and will be acquiring Viokace as a […]readmore
Shots: Lupin’s subsidiary Nanomi to sell its entire stake (99.82%) in Kyowa to Unison’s entity Plutus in an all-cash transaction for an enterprise value of ~$525.87M and will generate post-tax […]readmore